Must have felt a little constrained at MEDI!
Scientists in Search Of a Breakthrough
washtech.com
By Ellen McCarthy,
Washington Post Staff Writer
Monday, October 22, 2001
The 11 years Scott Koenig spent as a research director at MedImmune Inc. were good ones. In that time the company evolved from a 30-person startup firm to a profitable, high-profile company with a head count well into the hundreds.
Koenig enjoyed the success and stability he had achieved with MedImmune but eventually found himself missing the excitement of cutting-edge experiments and hands-on lab work.
So, when he was offered the chance to join a team of 10 scientists working in labs around the country on new techniques to fight cancer and other diseases, Koenig jumped aboard.
The scientists had been investigating the disease-fighting power of antibodies. The research was slow going until recently, when technology allowed antibodies to be studied and manipulated more easily.
So they decided to make a company out of their efforts. MacroGenics Inc. was incorporated last year and had already received venture funding, but Koenig was hired last month to make it a viable company. Koenig's job has been to find lab space in Rockville and lead a core team of researchers and, eventually, develop new products.
Four weeks into his new career as a chief executive, Koenig said he is loving life.
NOTE: I listened to the MEDI CC and to J Young's presentation on the pipeline. He deadpanned every new compound to the point where he made it sound not very exciting. His presentation was, IMO, poor and not very professional. Overall, I feel that MEDI's earnings growth looks weak and their management needs a bit of a shakeup in the marketing and R&D areas. Mark |
